Clinical trial
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic…
NCT00234000 · Jonsson Comprehensive Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00234000 |
|---|---|
| Title | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes |
| Official title | A Phase I Multicenter Study of Arsenic Trioxide and Azacitidine in Patients With Myelodysplastic Syndromes |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | CTI BioPharma Industry Celgene Corporation |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | arsenic trioxide, azacitidine |
| Enrollment | 1 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2009 |
| First posted | Oct 6, 2005 |
| Last update posted | Jul 31, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: